Sihuan Pharmaceutical Holdings Group Ltd. (460) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Sihuan Pharmaceutical Holdings Group Ltd. (460) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sihuan Pharmaceutical Holdings Group Ltd. (460) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Sihuan Pharmaceutical Holdings Group Ltd. (460) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 23, 2016
39 pages — Published Sep 23, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical) is a pharmaceutical company that develops, manufactures and markets cardiovascular and cerebral vascular drugs. The companys cardio-cerebral vascular drug products comprise Aoliankang, Yeduojia, Yuanzhijiu, Oudimei, Yimaining, Qingtong, Quao, Chuanqing, Aogan and Kelinao/Anjieli. It offers other drugs which include Luoanming, Pojia, Zhuoao/Biao and Renao. Sihuan Pharmaceuticals products serve therapeutic areas of cardiovascular system, nervous system, anti-infective, metabolism and oncology. The company also develops first-to-market generic drugs.

Sihuan Pharmaceutical Holdings Group Ltd. (460) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information

  
Source:
Document ID
GDPH189706D
Country
Industry
Ticker
460=CN
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201642
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201661
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201671
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 201681
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 201692
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals &Healthcare, Deal Details1125
  Asset Purchase111
    Jilin Sihuan To Acquire Technology Of Pidotimod Injection From Guangzhou Boji Pharma111
  Partnerships121
    Sihuan Pharma Enters into Agreement with RaQualia Pharma121
    Covance Enters into Co-Development Agreement with Sihuan Pharma132
    Sihuan Pharma Forms Joint Venture with MSPEA and Euromax151
    Sihuan Enters into Co-Development Agreement with Academy of Military Medical Sciences161
    Sihuan Pharma Enters into Co-Development Agreement with Academy of Military Medical Sciences171
    to-BBB Enters Into R&D Agreement With Sun Moral International181
    Sihuan Pharma Holdings Enters Into Co-Marketing Agreement With Benxi Leilong Pharma191
  Licensing Agreements201
    NeuroVive Pharma Enters Into Licensing Agreement With Sihuan Pharma For CicloMulsion And NeuroStat202
  Equity Offering221
    Sihuan Pharma Rumored For Public Offering Of Shares For US$147 Million221
    Sihuan Pharma Completes IPO Of US$741 Million232
  Acquisition251
    Sihuan Pharma to Acquire 70.7% Stake in Beijing Boren Hospital for USD14.6 million251
    Morgan Stanley Private Equity Asia To Divest Stake In Sihuan Pharma For Upto US$146.4 Million261
    Sihuan Pharma Acquires 40% Stake in XuanZhu Pharma271
    Shandong Buchang Completes Acquisition Of 19% Stake In Jilin Sichang Pharma For US$37 Million282
    Sihuan Pharma Completes Acquisition Of 100% Stake In Smart Baskets Investments From Congio Enterprises302
    Sihuan Pharma Completes Acquisition Of Dupromise From JSAB Investment For Upto US$361 Million322
    Jilin Sihuan Pharma Completes Acquisition Of 80% Stake In Changchun Xiangtong Pharma For US$21 Million342
Sihuan Pharmaceutical Holdings Group Ltd. - Key Competitors361
Key Employees371
Locations And Subsidiaries381
  Head Office381
  Other Locations &Subsidiaries381
Appendix391
  Methodology391
  About GlobalData391
  Contact Us391
  Disclaimer391

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Sihuan Pharmaceutical Holdings Group Ltd. (460) - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 23, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Sihuan-Pharmaceutical-Holdings-Group-Ltd-460-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-7594>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Sihuan Pharmaceutical Holdings Group Ltd. (460) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 23, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Sihuan-Pharmaceutical-Holdings-Group-Ltd-460-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-7594>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research